Patrick Dillon, MD – University of Virginia
Kathleen Haden, MSN, RN, ANP – University of Virginia
Craig L. Slingluff Jr., MD – University of Virginia
Specifically designed for clinical oncologists, registered nurses, pharmacists and the entire medical team involved in treating cancer patients with immunotherapy, this introductory, CME- and CE-certified program provided an overview of basic immunology principles and the mechanisms and clinical applications of immunotherapy for melanoma, lung cancer and genitourinary cancers.
Presented by leading authorities in tumor immunology and cancer immunotherapy, this program will facilitated understanding of 1) the basic principles of tumor immunology and immunotherapy, 2) the clinical indications for immunotherapy and the appropriate selection and management of patients, 3) emerging concepts and agents in the cancer immunotherapy field, and 4) the therapeutic effectiveness of immunotherapy to ultimately improve patient outcomes.
Attendees may also took advantage of the opportunity for professional networking that promoted collaboration and scientific exchange with experts, clinical oncologists and other health care providers from the surrounding community.
The target audience for this program was patient care providers and others who wish to learn the basic principles of tumor immunology and immunotherapy, and to improve their ability to integrate immunotherapy into state-of-the art clinical management for their patients. This intended audience includes clinical oncologists, registered nurses, nurse practitioners, pharmacists, allied health professionals, other patient care providers, students and patient advocates.
Attendees were able to review the PRE-PROGRAM VIDEO on tumor immunology. Module 1: Immunology and Immunotherapy 101 for the Non-Immunologist provides an overview of immunology principles that was covered during the program that provided a basis for understanding the mechanisms of immunotherapy approaches. The program on October 14 began by offering attendees the opportunity to ask questions about these slides, followed by a presentation about this information, especially as it pertains to immunotherapy. An optional additional 0.75 CME/CE credits are available for completing this module.
Upon completion of this program, participants are able to:
Asim Amin, MD, PhD – Levine Cancer Institute Carolinas Medical Center
Joseph W. Fay, MD – Baylor University Medical Center
Hideho Okada, MD, PhD – University of California San Francisco
John D. Powderly II, MD, CPI – Carolina BioOncology Institute, PLLC
Brian I. Rini, MD – Cleveland Clinic Taussig Cancer Center
Alexander Spira, MD, PhD – Virginia Cancer Specialists
Laura S. Wood, RN, MSN, OCN – Cleveland Clinic Taussig Cancer Center
Eleni Yeatras, RPh, BCOP – Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer
In collaboration with University of Virginia Cancer Center
The Advances in Cancer Immunotherapy™ series is supported in part by independent medical educational grants from AstraZeneca, Bristol-Myers Squibb, Genentech, and Merck & Co., Inc.
Event staff will be glad to assist you with any special needs (i.e., physical, dietary, etc.). Please contact SITC prior to the live event at (414) 271-2456.
View a list of upcoming Advances in Cancer ImmunotherapyTM 2016 regional programs.